[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEiq9gwRfLm1mPaBHRG7mgn5mQcHKOE3YZhUGIuBnAn4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University Hospital, Lille",[4],624,false,154,31,249368,41,492,[14,17,19,22,25,28,30,33],{"name":15,"count":16},"Obesity",14,{"name":18,"count":16},"Sars-CoV2",{"name":20,"count":21},"Critical Illness",11,{"name":23,"count":24},"Stroke",10,{"name":26,"count":27},"Systemic Sclerosis",9,{"name":29,"count":27},"Parkinson Disease",{"name":31,"count":32},"Parkinson's Disease",8,{"name":34,"count":32},"Inflammatory Bowel Diseases",[36,41,45,50,55,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02872571","Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy","2026-04","Intramuscular Islet Autograft",{"nctId":42,"briefTitle":43,"date":39,"intervention":44},"NCT05572229","Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","Teclistamab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04400539","The IMmunotherapy Pleural 5-ALA PDT","2026-05-09","Nivolumab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05664035","Frequency of SPAD in Adult Patients","2026-06","Diagnosis of SPAD using immunization with PPV23",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05406037","Biomarkers for Invasive Mucormycosis","2026-07","Venous sample",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06956482","PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis","2026-08","N-Acetylcysteine (NAC) Treatment",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06110403","Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","2026-09","TRIXEO AEROSPHERE",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05699005","Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO","2026-09-18","Packed Red Blood Cells",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05288842","Tanycytes in Alzheimer's Disease and Frontotemporal Dementia","2026-10","Lumbar puncture",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03993912","Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","2026-10-07","Daratumumab SC in combination with Lenalidomide",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,120,158,184,212,237,261,279,297,323,341,359,392,418,446,468,491,518,536,561,585,606,624,642,668,688,714,738,764,797,834,859,887,920,947,969,996,1014,1038,1063,1087,1109,1151,1187,1221,1246,1271,1289,1307,1332,1357,1381,1409,1427,1445,1463,1489,1529,1565,1588,1612,1638,1664,1682,1700,1726,1751,1777,1795,1813,1839,1857,1883,1901,1919,1945,1963,1988,2006,2032,2050,2068,2086,2111,2137,2155,2173,2191,2216,2234,2258,2283,2301,2335,2361,2385,2412,2430,2448,2472,2497,2521,2545,2570,2594,2619,2637,2664,2690,2715,2740,2764,2788,2811,2839,2865,2888,2914,2932,2994,3035,3067,3101,3139,3161,3189,3213,3238,3256,3274,3298,3331,3356,3374,3397,3421,3444,3468,3493,3516,3540,3562,3586,3611,3629,3654,3680,3708,3731,3758,3776,3801,3819,3844,3870],{"intervention":94,"totalTrials":95,"cells":96},"OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":118},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":53,"enrollment":114,"conditions":115,"interventions":117},"NCT07461272","Self-hangIng Patient and Hyperbaric Oxygen Therapy _ SIPHON Study","NOT_YET_RECRUITING",[90],"2028-12",50,[116],"Suicide",[94],{"trials":119,"activeCount":99},[],{"intervention":121,"totalTrials":122,"cells":123},"Prednisolone",2,{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":154,"NA":156},{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":95,"soonestReadout":63},[132,145],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":143},"NCT02281929","Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone","COMPLETED",[89],"2019-11-19","2015-06-13",297,[141,142],"Alcoholic Hepatitis","Alcoholic Liver Disease",[144,121],"Amoxicillin",{"nctId":61,"briefTitle":62,"status":146,"phases":147,"primaryCompletion":63,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"RECRUITING",[89],"2030-05","2026-05-22",477,[141],[64,121,153],"Prednisolone 10mg",{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":99},[],{"intervention":159,"totalTrials":95,"cells":160},"Cryotherapy + Tirbanibulin",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":180,"NA":182},{"trials":162,"activeCount":99},[],{"trials":164,"activeCount":99},[],{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":95,"soonestReadout":173},[169],{"nctId":170,"briefTitle":171,"status":111,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":179},"NCT07273656","Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead",[89],"2028-11-30","2026-11-30",59,[177,178],"Keratosis","Actinic Keratoses",[159],{"trials":181,"activeCount":99},[],{"trials":183,"activeCount":99},[],{"intervention":185,"totalTrials":95,"cells":186},"Apixaban 5 MG",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":208,"NA":210},{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":95,"soonestReadout":199},[195],{"nctId":196,"briefTitle":197,"status":146,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":207},"NCT03243175","Avoiding Anticoagulation After IntraCerebral Haemorrhage",[89],"2029-01","2029-12","2019-01-17",300,[204,205,206],"Intracerebral Hemorrhage","Atrial Fibrillation","Microhaemorrhage",[185],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"intervention":213,"totalTrials":95,"cells":214},"Caffeine",{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":233,"NA":235},{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":95,"soonestReadout":227},[223],{"nctId":224,"briefTitle":225,"status":146,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT04570085","Effect of CAFfeine on Cognition in Alzheimer's Disease",[89],"2027-12","2021-03-01",248,[231],"Alzheimer Disease",[213],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":257,"NA":259},{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":95,"soonestReadout":83},[247],{"nctId":81,"briefTitle":82,"status":248,"phases":249,"primaryCompletion":83,"completion":83,"start":250,"enrollment":251,"conditions":252,"interventions":254},"ACTIVE_NOT_RECRUITING",[89],"2019-10-17",294,[253],"Multiple Myeloma",[84,255,256],"Lenalidomide PO","Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression",{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"intervention":255,"totalTrials":95,"cells":262},{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":275,"NA":277},{"trials":264,"activeCount":99},[],{"trials":266,"activeCount":99},[],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":95,"soonestReadout":83},[271],{"nctId":81,"briefTitle":82,"status":248,"phases":272,"primaryCompletion":83,"completion":83,"start":250,"enrollment":251,"conditions":273,"interventions":274},[89],[253],[84,255,256],{"trials":276,"activeCount":99},[],{"trials":278,"activeCount":99},[],{"intervention":256,"totalTrials":95,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":293,"NA":295},{"trials":282,"activeCount":99},[],{"trials":284,"activeCount":99},[],{"trials":286,"activeCount":99},[],{"trials":288,"activeCount":95,"soonestReadout":83},[289],{"nctId":81,"briefTitle":82,"status":248,"phases":290,"primaryCompletion":83,"completion":83,"start":250,"enrollment":251,"conditions":291,"interventions":292},[89],[253],[84,255,256],{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":99},[],{"intervention":298,"totalTrials":95,"cells":299},"Clomiphene Citrate",{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":319,"NA":321},{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":99},[],{"trials":305,"activeCount":99},[],{"trials":307,"activeCount":95,"soonestReadout":312},[308],{"nctId":309,"briefTitle":310,"status":146,"phases":311,"primaryCompletion":312,"completion":227,"start":313,"enrollment":314,"conditions":315,"interventions":318},"NCT03059173","Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome",[89],"2027-09-12","2023-09-12",276,[316,317],"Polycystic Ovary Syndrome","Reproductive Medicine",[298],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"intervention":64,"totalTrials":95,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":337,"NA":339},{"trials":326,"activeCount":99},[],{"trials":328,"activeCount":99},[],{"trials":330,"activeCount":99},[],{"trials":332,"activeCount":95,"soonestReadout":63},[333],{"nctId":61,"briefTitle":62,"status":146,"phases":334,"primaryCompletion":63,"completion":148,"start":149,"enrollment":150,"conditions":335,"interventions":336},[89],[141],[64,121,153],{"trials":338,"activeCount":99},[],{"trials":340,"activeCount":99},[],{"intervention":153,"totalTrials":95,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":355,"NA":357},{"trials":344,"activeCount":99},[],{"trials":346,"activeCount":99},[],{"trials":348,"activeCount":99},[],{"trials":350,"activeCount":95,"soonestReadout":63},[351],{"nctId":61,"briefTitle":62,"status":146,"phases":352,"primaryCompletion":63,"completion":148,"start":149,"enrollment":150,"conditions":353,"interventions":354},[89],[141],[64,121,153],{"trials":356,"activeCount":99},[],{"trials":358,"activeCount":99},[],{"intervention":360,"totalTrials":122,"cells":361},"Daratumumab",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":386,"PHASE4":388,"NA":390},{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"trials":367,"activeCount":95,"soonestReadout":39},[368,378],{"nctId":369,"briefTitle":370,"status":135,"phases":371,"primaryCompletion":372,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":376},"NCT02626481","Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma",[88],"2020-03-09","2015-12-28",64,[253],[360,377],"Dexamethasone",{"nctId":42,"briefTitle":43,"status":146,"phases":379,"primaryCompletion":39,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},[88],"2030-09","2023-12-21",74,[253],[44,360,385],"Lenalidomide",{"trials":387,"activeCount":99},[],{"trials":389,"activeCount":99},[],{"trials":391,"activeCount":99},[],{"intervention":393,"totalTrials":95,"cells":394},"Benralizumab 30 MG\u002FML [Fasenra]",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":412,"PHASE4":414,"NA":416},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":95,"soonestReadout":405},[401],{"nctId":402,"briefTitle":403,"status":111,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT06734884","Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)",[88],"2029-01-05","2029-09-01","2027-01-06",96,[410],"DRESS Syndrome",[393],{"trials":413,"activeCount":99},[],{"trials":415,"activeCount":99},[],{"trials":417,"activeCount":99},[],{"intervention":419,"totalTrials":95,"cells":420},"intraportal islet autotransplantation",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":422,"activeCount":99},[],{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":95,"soonestReadout":431},[427],{"nctId":428,"briefTitle":429,"status":146,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":439},"NCT05116072","Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula",[87,88],"2028-02-20","2030-02-20","2022-02-20",36,[436,437,438],"Adenocarcinoma of the Pancreas","Adenocarcinoma of the Duodenum","Ampullary Adenocarcinoma",[419],{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"trials":445,"activeCount":99},[],{"intervention":49,"totalTrials":95,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":95,"soonestReadout":48},[454],{"nctId":46,"briefTitle":47,"status":146,"phases":455,"primaryCompletion":48,"completion":48,"start":456,"enrollment":457,"conditions":458,"interventions":461},[88],"2022-05-09",20,[459,460],"Mesotheliomas Pleural","Malignant Pleural Mesothelioma",[49],{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":99},[],{"trials":467,"activeCount":99},[],{"intervention":469,"totalTrials":95,"cells":470},"fluoroethyl-L tyrosine",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":95,"soonestReadout":380},[477],{"nctId":478,"briefTitle":479,"status":111,"phases":480,"primaryCompletion":380,"completion":380,"start":68,"enrollment":481,"conditions":482,"interventions":484},"NCT07360548","Study of 18FET PET in Functional Pituitary Adenomas With Indeterminate MRI Findings",[88],30,[483],"Functional Pituitary Adenomas",[469],{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":99},[],{"intervention":492,"totalTrials":95,"cells":493},"rapamycin",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":495,"activeCount":99},[],{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":95,"soonestReadout":504},[500],{"nctId":501,"briefTitle":502,"status":146,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":510},"NCT03243019","Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations",[88],"2027-02","2018-06-25",28,[508,509],"Lymphatic Malformation","Pediatric",[492,511],"Rapamycin dosage",{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":99},[],{"intervention":511,"totalTrials":95,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[],{"trials":525,"activeCount":95,"soonestReadout":504},[526],{"nctId":501,"briefTitle":502,"status":146,"phases":527,"primaryCompletion":504,"completion":504,"start":505,"enrollment":506,"conditions":528,"interventions":529},[88],[508,509],[492,511],{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":99},[],{"trials":535,"activeCount":99},[],{"intervention":537,"totalTrials":95,"cells":538},"EXL01",{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":540,"activeCount":99},[],{"trials":542,"activeCount":99},[],{"trials":544,"activeCount":95,"soonestReadout":549},[545],{"nctId":546,"briefTitle":547,"status":146,"phases":548,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":554},"NCT06448572","EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.",[87,88],"2028-10-01","2024-07-16",21,[553],"Non-Small Cell Lung Cancer",[537],{"trials":556,"activeCount":99},[],{"trials":558,"activeCount":99},[],{"trials":560,"activeCount":99},[],{"intervention":562,"totalTrials":95,"cells":563},"DRF",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":95,"soonestReadout":574},[570],{"nctId":571,"briefTitle":572,"status":146,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT07275515","DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL",[88],"2029-05","2026-05-19",192,[23],[562],{"trials":580,"activeCount":99},[],{"trials":582,"activeCount":99},[],{"trials":584,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":588,"activeCount":99},[],{"trials":590,"activeCount":99},[],{"trials":592,"activeCount":95,"soonestReadout":39},[593],{"nctId":37,"briefTitle":38,"status":248,"phases":594,"primaryCompletion":39,"completion":39,"start":595,"enrollment":596,"conditions":597,"interventions":599},[87,88],"2013-03",35,[598],"Disorder of Endocrine Pancreas",[40],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"intervention":44,"totalTrials":95,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":609,"activeCount":99},[],{"trials":611,"activeCount":99},[],{"trials":613,"activeCount":95,"soonestReadout":39},[614],{"nctId":42,"briefTitle":43,"status":146,"phases":615,"primaryCompletion":39,"completion":380,"start":381,"enrollment":382,"conditions":616,"interventions":617},[88],[253],[44,360,385],{"trials":619,"activeCount":99},[],{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"intervention":385,"totalTrials":95,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":95,"soonestReadout":39},[632],{"nctId":42,"briefTitle":43,"status":146,"phases":633,"primaryCompletion":39,"completion":380,"start":381,"enrollment":382,"conditions":634,"interventions":635},[88],[253],[44,360,385],{"trials":637,"activeCount":99},[],{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"intervention":643,"totalTrials":95,"cells":644},"Vismodegib",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":95,"soonestReadout":655},[651],{"nctId":652,"briefTitle":653,"status":146,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":661},"NCT05561634","Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma",[88],"2029-06-20","2023-06-20",82,[659,660],"Basal Cell Carcinoma","Radiotherapy; Complications",[643],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":99},[],{"intervention":69,"totalTrials":95,"cells":669},{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":671,"activeCount":99},[],{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":95,"soonestReadout":68},[676],{"nctId":66,"briefTitle":67,"status":146,"phases":677,"primaryCompletion":68,"completion":68,"start":678,"enrollment":596,"conditions":679,"interventions":681},[87,88],"2023-09-29",[680],"Copd",[69],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"trials":687,"activeCount":99},[],{"intervention":689,"totalTrials":95,"cells":690},"CAR-T cell therapy",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":95,"soonestReadout":699},[695],{"nctId":696,"briefTitle":697,"status":146,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT06649227","Study Investigating the Safety of CD19 CAR-T Cells in Relapsed\u002FRefractory AML Expressing CD19",[87],"2029-07-10","2030-07-10","2025-07-10",5,[704],"Relapsed Adult AML",[689],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"intervention":715,"totalTrials":95,"cells":716},"Surgery with Neoadjuvant stereotactic body radiation therapy",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":718,"activeCount":99},[],{"trials":720,"activeCount":95,"soonestReadout":725},[721],{"nctId":722,"briefTitle":723,"status":146,"phases":724,"primaryCompletion":725,"completion":199,"start":726,"enrollment":481,"conditions":727,"interventions":729},"NCT04587739","Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.",[87],"2028-01","2021-01-31",[728],"Hepatocellular Carcinoma",[715],{"trials":731,"activeCount":99},[],{"trials":733,"activeCount":99},[],{"trials":735,"activeCount":99},[],{"trials":737,"activeCount":99},[],{"intervention":74,"totalTrials":95,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":756,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":741,"activeCount":99},[],{"trials":743,"activeCount":95,"soonestReadout":73},[744],{"nctId":71,"briefTitle":72,"status":146,"phases":745,"primaryCompletion":73,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":755},[87],"2026-12-18","2023-09-18",236,[750,751,752,753,754],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Transfusion Related Complication","Anemia","Oxygen Delivery",[74],{"trials":757,"activeCount":99},[],{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"intervention":765,"totalTrials":122,"cells":766},"blood sample",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":768,"activeCount":99},[],{"trials":770,"activeCount":99},[],{"trials":772,"activeCount":99},[],{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"trials":778,"activeCount":122,"soonestReadout":78},[779,790],{"nctId":780,"briefTitle":781,"status":146,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":789},"NCT04119908","Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases",[91],"2028-05-24","2023-05-24",400,[787,788],"Von Willebrand Diseases","Glanzmann Thrombasthenia",[765],{"nctId":76,"briefTitle":77,"status":146,"phases":791,"primaryCompletion":78,"completion":78,"start":792,"enrollment":793,"conditions":794,"interventions":796},[],"2022-09-06",102,[231,795],"Frontotemporal Dementia",[79,765],{"intervention":798,"totalTrials":122,"cells":799},"Blood test",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":99},[],{"trials":807,"activeCount":99},[],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":95,"soonestReadout":816},[812,822],{"nctId":813,"briefTitle":814,"status":111,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":818,"conditions":819,"interventions":821},"NCT07425028","Evaluation of an Intensified Systematic Screening for Congenital Hypothyroidism in Premature Newborns",[],"2028-03","2027-03",1600,[820],"Congenital Hypothyroidism",[798],{"nctId":823,"briefTitle":824,"status":135,"phases":825,"primaryCompletion":826,"completion":826,"start":228,"enrollment":827,"conditions":828,"interventions":832},"NCT04746313","Prevalence of Hyperprolactinemia in Systemic Scleroderma",[],"2021-05-12",71,[829,830,831],"Sclerosis, Systemic","Scleroderma","Hyperprolactinemia",[833],"blood test",{"intervention":835,"totalTrials":95,"cells":836},"Systemic treatment",{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":95,"soonestReadout":853},[849],{"nctId":850,"briefTitle":851,"status":146,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":858},"NCT07606508","Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.",[],"2036-07-15","2021-07-09",1500,[857],"Cutaneous Squamous Cell Carcinoma (CSCC)",[835],{"intervention":860,"totalTrials":95,"cells":861},"Large and early multigene sequencing",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":95,"soonestReadout":878},[874],{"nctId":875,"briefTitle":876,"status":111,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":886},"NCT06958224","Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers",[91],"2028-11-10","2029-01-09","2026-04-10",360,[883,884,885],"Breast Cancer","Liver Cancer","Pancreatic Ductal Adenocarcinoma",[860],{"intervention":888,"totalTrials":95,"cells":889},"Biobanking with genetic analysis",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":95,"soonestReadout":906},[902],{"nctId":903,"briefTitle":904,"status":146,"phases":905,"primaryCompletion":906,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":919},"NCT04334031","Deployment o the Multidisciplinary Prospective Cohort Imminent",[91],"2031-07-20","2031-07-21","2020-07-20",2200,[911,912,913,914,915,916,917,26,918],"Chronic Inflammatory Disease","Angioedema","Severe Asthma","Lupus","Atopic Dermatitis","Psoriatic Arthritis","Multiple Sclerosis","Behçet Disease",[888],{"intervention":921,"totalTrials":95,"cells":922},"Biological sample",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":95,"soonestReadout":939},[935],{"nctId":936,"briefTitle":937,"status":146,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":946},"NCT04018118","Natural History of Hypereosinophilia and Hypereosinophilic Syndromes",[],"2029-05-06","2031-05","2019-05-06",600,[944,945],"Eosinophilia","Hypereosinophilic Syndrome",[921],{"intervention":59,"totalTrials":95,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":99},[],{"trials":956,"activeCount":99},[],{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":95,"soonestReadout":58},[961],{"nctId":56,"briefTitle":57,"status":146,"phases":962,"primaryCompletion":58,"completion":58,"start":963,"enrollment":964,"conditions":965,"interventions":968},[],"2023-11-29",100,[966,967],"Mucorales Infection","Mucormycosis",[59],{"intervention":970,"totalTrials":95,"cells":971},"Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":973,"activeCount":99},[],{"trials":975,"activeCount":99},[],{"trials":977,"activeCount":99},[],{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":95,"soonestReadout":988},[984],{"nctId":985,"briefTitle":986,"status":146,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":995},"NCT06501807","BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry",[91],"2034-09-02","2035-01-02","2024-07-11",900,[993,994],"Rhinosinusitis Chronic","Nasal Polyps",[970],{"intervention":79,"totalTrials":95,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":99},[],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":95,"soonestReadout":78},[1010],{"nctId":76,"briefTitle":77,"status":146,"phases":1011,"primaryCompletion":78,"completion":78,"start":792,"enrollment":793,"conditions":1012,"interventions":1013},[],[231,795],[79,765],{"intervention":1015,"totalTrials":95,"cells":1016},"Biologic treatments available in CRSwNP",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1018,"activeCount":99},[],{"trials":1020,"activeCount":99},[],{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":95,"soonestReadout":1033},[1029],{"nctId":1030,"briefTitle":1031,"status":248,"phases":1032,"primaryCompletion":1033,"completion":1033,"start":1034,"enrollment":964,"conditions":1035,"interventions":1037},"NCT05228041","BIOlogics in Severe Nasal POlyposis SurvEy",[],"2027-07","2022-02-10",[1036],"Chronic Rhinosinusitis With Nasal Polyps",[1015],{"intervention":1039,"totalTrials":95,"cells":1040},"Biological biomarkers",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":99},[],{"trials":1048,"activeCount":99},[],{"trials":1050,"activeCount":99},[],{"trials":1052,"activeCount":95,"soonestReadout":1057},[1053],{"nctId":1054,"briefTitle":1055,"status":146,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1060,"interventions":1062},"NCT04621357","Influence of Cerebral Oedema in Intracerebral Haemorrhage",[91],"2027-12-03","2021-06-04",500,[23,1061],"Intra Cerebral Hemorrhage",[1039],{"intervention":1064,"totalTrials":95,"cells":1065},"DNA banking",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":99},[],{"trials":1077,"activeCount":95,"soonestReadout":1082},[1078],{"nctId":1079,"briefTitle":1080,"status":146,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1059,"conditions":1084,"interventions":1086},"NCT03387865","A Clinico-biological Database of Lung Cancers",[],"2032-03","2019-03-13",[1085],"Lung Cancer",[1064],{"intervention":54,"totalTrials":95,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":95,"soonestReadout":53},[1101],{"nctId":51,"briefTitle":52,"status":146,"phases":1102,"primaryCompletion":53,"completion":53,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1108},[],"2023-03-01",99,[1106,1107],"Specific Antibody Deficiency","Predominantly Antibody Deficiencies",[54],{"intervention":1110,"totalTrials":122,"cells":1111},"Saline Solution",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1134,"NA":1149},{"trials":1113,"activeCount":99},[],{"trials":1115,"activeCount":99},[],{"trials":1117,"activeCount":99},[],{"trials":1119,"activeCount":99},[1120],{"nctId":1121,"briefTitle":1122,"status":135,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1131},"NCT02702128","Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery",[89],"2018-06-30","2016-01-03",157,[1128,1129,1130],"Peri-operative Hemorrhage or Hematoma","Surgery","Retrognathism",[1132,1133],"Tranexamic Acid","saline solution",{"trials":1135,"activeCount":99},[1136],{"nctId":1137,"briefTitle":1138,"status":135,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1146},"NCT02797119","Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery",[90],"2021-04-15","2016-03-15",225,[1144,1145],"Pregnancy Complications","Hemorrhage",[1147,1148,1110],"tranexamic acid 1 g","tranexamic acid 0.5 g",{"trials":1150,"activeCount":99},[],{"intervention":1152,"totalTrials":122,"cells":1153},"Methylphenidate",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1169,"PHASE4":1171,"NA":1185},{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[1160],{"nctId":1161,"briefTitle":1162,"status":135,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":9,"conditions":1166,"interventions":1168},"NCT03280251","Methylphenidate and Cognitive Training in Elderly",[88],"2020-03-11","2018-09-19",[1167],"Healthy Volunteers",[1152],{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[1173],{"nctId":1174,"briefTitle":1175,"status":135,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":1179,"conditions":1180,"interventions":1183},"NCT00914095","Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)",[90],"2011-12","2009-10",69,[31,1181,1182],"Gait Disorders, Neurologic","Dementia",[1184],"methylphenidate",{"trials":1186,"activeCount":99},[],{"intervention":1188,"totalTrials":122,"cells":1189},"memantine",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1219},{"trials":1191,"activeCount":99},[],{"trials":1193,"activeCount":99},[1194],{"nctId":1195,"briefTitle":1196,"status":1197,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":481,"conditions":1201,"interventions":1203},"NCT02288000","Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases","TERMINATED",[87],"2020-12-31","2016-09-14",[231,1202],"Battery",[1204],"Memantine",{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[1211],{"nctId":1212,"briefTitle":1213,"status":135,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1178,"enrollment":506,"conditions":1217,"interventions":1218},"NCT01108029","Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease",[90],"2010-09","2010-10",[31,1181],[1188],{"trials":1220,"activeCount":99},[],{"intervention":1222,"totalTrials":95,"cells":1223},"Clindamycin",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1244},{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[1234],{"nctId":1235,"briefTitle":1236,"status":135,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT00642980","Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis",[90],"2011-06","2006-04",3105,[1242],"Pregnancy",[1222,1222],{"trials":1245,"activeCount":99},[],{"intervention":1247,"totalTrials":95,"cells":1248},"ropivacaine plus clonidine",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1255,"PHASE4":1257,"NA":1269},{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[1259],{"nctId":1260,"briefTitle":1261,"status":135,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1268},"NCT02778178","TAP Block Efficacy After Lumbar Spine Surgery Through Anterior Approach: a Randomized, Placebo-controlled Study",[90],"2017-04","2016-05-02",40,[1267],"Pain, Postoperative",[1247],{"trials":1270,"activeCount":99},[],{"intervention":1147,"totalTrials":95,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1287},{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[1283],{"nctId":1137,"briefTitle":1138,"status":135,"phases":1284,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1285,"interventions":1286},[90],[1144,1145],[1147,1148,1110],{"trials":1288,"activeCount":99},[],{"intervention":1148,"totalTrials":95,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1299,"NA":1305},{"trials":1292,"activeCount":99},[],{"trials":1294,"activeCount":99},[],{"trials":1296,"activeCount":99},[],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[1301],{"nctId":1137,"briefTitle":1138,"status":135,"phases":1302,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":1142,"conditions":1303,"interventions":1304},[90],[1144,1145],[1147,1148,1110],{"trials":1306,"activeCount":99},[],{"intervention":1308,"totalTrials":95,"cells":1309},"optimized medical management",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1330},{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":99},[1320],{"nctId":1321,"briefTitle":1322,"status":135,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1329},"NCT01501201","Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients",[90],"2019-09-27","2011-08-08",66,[15,1328],"Diabetes",[1308],{"trials":1331,"activeCount":99},[],{"intervention":1333,"totalTrials":95,"cells":1334},"Baclofen",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1343,"NA":1355},{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[],{"trials":1340,"activeCount":99},[],{"trials":1342,"activeCount":99},[],{"trials":1344,"activeCount":99},[1345],{"nctId":1346,"briefTitle":1347,"status":1197,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1354},"NCT02596763","Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder",[90],"2018-12-24","2015-12-24",239,[1353],"Alcohol Use Disorder",[1333],{"trials":1356,"activeCount":99},[],{"intervention":1358,"totalTrials":95,"cells":1359},"midazolam intravenous administration",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1379},{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[],{"trials":1365,"activeCount":99},[],{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[1370],{"nctId":1371,"briefTitle":1372,"status":135,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":175,"conditions":1376,"interventions":1378},"NCT02213302","Premedication by Midazolam for Emergency Surgery",[90],"2016-01","2014-07",[1377],"Anxiety",[1358],{"trials":1380,"activeCount":99},[],{"intervention":1382,"totalTrials":95,"cells":1383},"ceftriaxone",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1407},{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[1394],{"nctId":1395,"briefTitle":1396,"status":1197,"phases":1397,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT03012360","Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis",[90],"2024-07-07","2018-02-08",103,[1402,20],"Mechanical Ventilation Complication",[1382,1404,1405,1406],"ciprofloxacin","imipenem","linezolid",{"trials":1408,"activeCount":99},[],{"intervention":1404,"totalTrials":95,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1425},{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[1421],{"nctId":1395,"briefTitle":1396,"status":1197,"phases":1422,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1423,"interventions":1424},[90],[1402,20],[1382,1404,1405,1406],{"trials":1426,"activeCount":99},[],{"intervention":1405,"totalTrials":95,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1443},{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[1439],{"nctId":1395,"briefTitle":1396,"status":1197,"phases":1440,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1441,"interventions":1442},[90],[1402,20],[1382,1404,1405,1406],{"trials":1444,"activeCount":99},[],{"intervention":1406,"totalTrials":95,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1455,"NA":1461},{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[1457],{"nctId":1395,"briefTitle":1396,"status":1197,"phases":1458,"primaryCompletion":1398,"completion":1398,"start":1399,"enrollment":1400,"conditions":1459,"interventions":1460},[90],[1402,20],[1382,1404,1405,1406],{"trials":1462,"activeCount":99},[],{"intervention":1464,"totalTrials":95,"cells":1465},"IgHy10",{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1472,"PHASE4":1474,"NA":1487},{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":99},[1476],{"nctId":1477,"briefTitle":1478,"status":135,"phases":1479,"primaryCompletion":1480,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1486},"NCT02881437","IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia",[90],"2018-03-16","2018-11","2016-11-11",22,[1485],"Primary Immunodeficiency",[1464],{"trials":1488,"activeCount":99},[],{"intervention":377,"totalTrials":1490,"cells":1491},3,{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1512,"PHASE4":1525,"NA":1527},{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[1498,1502],{"nctId":369,"briefTitle":370,"status":135,"phases":1499,"primaryCompletion":372,"completion":372,"start":373,"enrollment":374,"conditions":1500,"interventions":1501},[88],[253],[360,377],{"nctId":1503,"briefTitle":1504,"status":135,"phases":1505,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":1509,"interventions":1510},"NCT01745640","Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)",[88],"2015-12","2012-01",63,[253],[1511,377],"POMALIDOMIDE",{"trials":1513,"activeCount":99},[1514],{"nctId":1515,"briefTitle":1516,"status":135,"phases":1517,"primaryCompletion":1518,"completion":1238,"start":1519,"enrollment":1326,"conditions":1520,"interventions":1522},"NCT01679093","Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.",[89],"2011-01","2009-06",[1521],"Interaction Between Antiemetic Drugs and Paracetamol",[1523,1524,377],"ondansetron","Droperidol",{"trials":1526,"activeCount":99},[],{"trials":1528,"activeCount":99},[],{"intervention":1530,"totalTrials":122,"cells":1531},"Ketamine",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1561,"NA":1563},{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[1540,1550],{"nctId":1541,"briefTitle":1542,"status":135,"phases":1543,"primaryCompletion":1544,"completion":1544,"start":1518,"enrollment":1545,"conditions":1546,"interventions":1547},"NCT02969733","The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy",[88,89],"2017-09",135,[1267],[1548,1530,1549],"Xylocaine","isotonic saline serum intravenous administration",{"nctId":1551,"briefTitle":1552,"status":135,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1559},"NCT02783430","Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease",[88,89],"2024-03-08","2016-09-08",42,[1558],"Depression",[1530,1560],"Milnacipran",{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[],{"intervention":1566,"totalTrials":95,"cells":1567},"Thalidomide",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1584,"NA":1586},{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[1576],{"nctId":1577,"briefTitle":1578,"status":135,"phases":1579,"completion":1580,"start":1581,"enrollment":1059,"conditions":1582,"interventions":1583},"NCT00367185","Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma",[89],"2005-10","2000-05",[253],[1566],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"intervention":1589,"totalTrials":95,"cells":1590},"rivastigmine",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1608,"NA":1610},{"trials":1592,"activeCount":99},[],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[1599],{"nctId":1600,"briefTitle":1601,"status":135,"phases":1602,"primaryCompletion":1177,"completion":1507,"start":1603,"enrollment":1265,"conditions":1604,"interventions":1607},"NCT00767091","Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia",[89],"2009-03",[31,1605,1606],"Apathy","no Dementia",[1589],{"trials":1609,"activeCount":99},[],{"trials":1611,"activeCount":99},[],{"intervention":1613,"totalTrials":95,"cells":1614},"Clonidine",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1634,"NA":1636},{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[1623],{"nctId":1624,"briefTitle":1625,"status":135,"phases":1626,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},"NCT03725930","Premedication by Clonidine Intranasal in Pediatric Surgery",[89],"2021-11-24","2023-11-24","2019-03-26",90,[1632],"Child Preschool",[1613],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"intervention":1639,"totalTrials":95,"cells":1640},"intrathecal morphine",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1660,"NA":1662},{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[1649],{"nctId":1650,"briefTitle":1651,"status":135,"phases":1652,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1657},"NCT03238430","Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia .",[88,89],"2019-05-25","2015-05-20",186,[1267],[1639,1658,1659],"Morphine PCA","Ropivacaine infiltration",{"trials":1661,"activeCount":99},[],{"trials":1663,"activeCount":99},[],{"intervention":1658,"totalTrials":95,"cells":1665},{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1678,"NA":1680},{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":99},[],{"trials":1671,"activeCount":99},[],{"trials":1673,"activeCount":99},[1674],{"nctId":1650,"briefTitle":1651,"status":135,"phases":1675,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":1655,"conditions":1676,"interventions":1677},[88,89],[1267],[1639,1658,1659],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[],{"intervention":1659,"totalTrials":95,"cells":1683},{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1696,"NA":1698},{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":99},[],{"trials":1689,"activeCount":99},[],{"trials":1691,"activeCount":99},[1692],{"nctId":1650,"briefTitle":1651,"status":135,"phases":1693,"primaryCompletion":1653,"completion":1653,"start":1654,"enrollment":1655,"conditions":1694,"interventions":1695},[88,89],[1267],[1639,1658,1659],{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"intervention":1701,"totalTrials":95,"cells":1702},"saline solution 0.9%",{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1709,"PHASE4":1722,"NA":1724},{"trials":1704,"activeCount":99},[],{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[1711],{"nctId":1712,"briefTitle":1713,"status":135,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1720},"NCT02821169","Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain",[89],"2019-06","2015-04",184,[1719],"Pain",[1721,1701],"ropivacaine",{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"intervention":1727,"totalTrials":95,"cells":1728},"Biological mesh",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1747,"NA":1749},{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[1737],{"nctId":1738,"briefTitle":1739,"status":135,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT01594450","Biological Meshes in Infected Fields: a Randomized Controlled Trial",[89],"2019-03-28","2012-05",110,[1745],"Ventral Hernia",[1727],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"intervention":1752,"totalTrials":95,"cells":1753},"Freezed-dried plasma",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1773,"NA":1775},{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"trials":1761,"activeCount":99},[1762],{"nctId":1763,"briefTitle":1764,"status":135,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1556,"conditions":1768,"interventions":1771},"NCT02750150","Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients",[89],"2016-04-17","2013-07-09",[1769,1770],"Trauma","Coagulopathy",[1752,1772],"Fresh-frozen plasma",{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"intervention":1772,"totalTrials":95,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[1787],{"nctId":1763,"briefTitle":1764,"status":135,"phases":1788,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1556,"conditions":1789,"interventions":1790},[89],[1769,1770],[1752,1772],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[],{"intervention":144,"totalTrials":95,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1809,"NA":1811},{"trials":1798,"activeCount":99},[],{"trials":1800,"activeCount":99},[],{"trials":1802,"activeCount":99},[],{"trials":1804,"activeCount":99},[1805],{"nctId":133,"briefTitle":134,"status":135,"phases":1806,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1807,"interventions":1808},[89],[141,142],[144,121],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"intervention":1814,"totalTrials":95,"cells":1815},"Preoperative Chemotherapy",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1835,"NA":1837},{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"trials":1821,"activeCount":99},[],{"trials":1823,"activeCount":99},[1824],{"nctId":1825,"briefTitle":1826,"status":1197,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1830,"conditions":1831,"interventions":1833},"NCT03042169","Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer",[89],"2024-08-28","2021-08-25",6,[1832],"Gastric Adenocarcinoma",[1814,1834],"Postoperative chemotherapy",{"trials":1836,"activeCount":99},[],{"trials":1838,"activeCount":99},[],{"intervention":1834,"totalTrials":95,"cells":1840},{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1853,"NA":1855},{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":99},[],{"trials":1848,"activeCount":99},[1849],{"nctId":1825,"briefTitle":1826,"status":1197,"phases":1850,"primaryCompletion":1828,"completion":1828,"start":1829,"enrollment":1830,"conditions":1851,"interventions":1852},[89],[1832],[1814,1834],{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[],{"intervention":1858,"totalTrials":95,"cells":1859},"Sodium Lactate light dose",{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1879,"NA":1881},{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[1868],{"nctId":1869,"briefTitle":1870,"status":135,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":175,"conditions":1874,"interventions":1876},"NCT03528213","Utility of Sodium Lactate Infusion During Septic Shock",[88,89],"2023-02-21","2019-10-04",[1875],"Septic Shock",[1858,1877,1878],"Sodium Lactate high dose","Normal saline",{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"intervention":1877,"totalTrials":95,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1891,"PHASE4":1897,"NA":1899},{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[],{"trials":1890,"activeCount":99},[],{"trials":1892,"activeCount":99},[1893],{"nctId":1869,"briefTitle":1870,"status":135,"phases":1894,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":175,"conditions":1895,"interventions":1896},[88,89],[1875],[1858,1877,1878],{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"intervention":1878,"totalTrials":95,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1915,"NA":1917},{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[1911],{"nctId":1869,"briefTitle":1870,"status":135,"phases":1912,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":175,"conditions":1913,"interventions":1914},[88,89],[1875],[1858,1877,1878],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[],{"intervention":1920,"totalTrials":95,"cells":1921},"Thymoglobulin",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1941,"NA":1943},{"trials":1923,"activeCount":99},[],{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[1930],{"nctId":1931,"briefTitle":1932,"status":135,"phases":1933,"primaryCompletion":1934,"completion":1934,"start":1935,"enrollment":1936,"conditions":1937,"interventions":1939},"NCT00682292","Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk",[89],"2006-11","2001-05",227,[1938],"Renal Transplantation",[1920,1940],"Daclizumab",{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"intervention":1940,"totalTrials":95,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[1955],{"nctId":1931,"briefTitle":1932,"status":135,"phases":1956,"primaryCompletion":1934,"completion":1934,"start":1935,"enrollment":1936,"conditions":1957,"interventions":1958},[89],[1938],[1920,1940],{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[],{"intervention":1964,"totalTrials":95,"cells":1965},"Hydroxychloroquine",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1984,"NA":1986},{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[],{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[1974],{"nctId":1975,"briefTitle":1976,"status":1977,"phases":1978,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":99,"conditions":1981,"interventions":1982},"NCT04372082","Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19","WITHDRAWN",[89],"2023-05","2020-05",[18],[1964,1983],"Association of diltiazem and niclosamide",{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[],{"intervention":1983,"totalTrials":95,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":1996,"PHASE4":2002,"NA":2004},{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"trials":1995,"activeCount":99},[],{"trials":1997,"activeCount":99},[1998],{"nctId":1975,"briefTitle":1976,"status":1977,"phases":1999,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":99,"conditions":2000,"interventions":2001},[89],[18],[1964,1983],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[],{"intervention":2007,"totalTrials":95,"cells":2008},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2015,"PHASE4":2028,"NA":2030},{"trials":2010,"activeCount":99},[],{"trials":2012,"activeCount":99},[],{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[2017],{"nctId":2018,"briefTitle":2019,"status":135,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2026},"NCT04173364","Interscalene Block and Dysfunction Diaphragmatic",[89],"2020-09-21","2019-10-29",60,[2025],"Diaphragmatic Paralysis",[2007,2027],"Ropivacaine 0.1% Injectable Solution",{"trials":2029,"activeCount":99},[],{"trials":2031,"activeCount":99},[],{"intervention":2027,"totalTrials":95,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2046,"NA":2048},{"trials":2035,"activeCount":99},[],{"trials":2037,"activeCount":99},[],{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[2042],{"nctId":2018,"briefTitle":2019,"status":135,"phases":2043,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":2023,"conditions":2044,"interventions":2045},[89],[2025],[2007,2027],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"intervention":1548,"totalTrials":95,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[],{"trials":2057,"activeCount":99},[],{"trials":2059,"activeCount":99},[2060],{"nctId":1541,"briefTitle":1542,"status":135,"phases":2061,"primaryCompletion":1544,"completion":1544,"start":1518,"enrollment":1545,"conditions":2062,"interventions":2063},[88,89],[1267],[1548,1530,1549],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"intervention":1549,"totalTrials":95,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[2078],{"nctId":1541,"briefTitle":1542,"status":135,"phases":2079,"primaryCompletion":1544,"completion":1544,"start":1518,"enrollment":1545,"conditions":2080,"interventions":2081},[88,89],[1267],[1548,1530,1549],{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"intervention":2087,"totalTrials":95,"cells":2088},"Clopidogrel or Aspirin and\u002For Dypyridamole",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2107,"NA":2109},{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[2097],{"nctId":2098,"briefTitle":2099,"status":1197,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":2103,"conditions":2104,"interventions":2106},"NCT02966119","REstart or STop Antithrombotic Randomised Trial in France",[89],"2019-12-07","2016-12-07",23,[2105],"Cerebral Hemorrhage",[2087],{"trials":2108,"activeCount":99},[],{"trials":2110,"activeCount":99},[],{"intervention":2112,"totalTrials":95,"cells":2113},"Gabapentin",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2133,"NA":2135},{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"trials":2121,"activeCount":99},[2122],{"nctId":2123,"briefTitle":2124,"status":135,"phases":2125,"primaryCompletion":2126,"completion":2126,"start":2127,"enrollment":2128,"conditions":2129,"interventions":2132},"NCT03158376","Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).",[89],"2019-05-24","2015-09",201,[2130,2131],"Postoperative Pain","Chronic Pain",[2112],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"intervention":1523,"totalTrials":95,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[2147],{"nctId":1515,"briefTitle":1516,"status":135,"phases":2148,"primaryCompletion":1518,"completion":1238,"start":1519,"enrollment":1326,"conditions":2149,"interventions":2150},[89],[1521],[1523,1524,377],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"intervention":1524,"totalTrials":95,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[2165],{"nctId":1515,"briefTitle":1516,"status":135,"phases":2166,"primaryCompletion":1518,"completion":1238,"start":1519,"enrollment":1326,"conditions":2167,"interventions":2168},[89],[1521],[1523,1524,377],{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"intervention":1560,"totalTrials":95,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":99},[],{"trials":2178,"activeCount":99},[],{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[2183],{"nctId":1551,"briefTitle":1552,"status":135,"phases":2184,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":2185,"interventions":2186},[88,89],[1558],[1530,1560],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"intervention":2192,"totalTrials":95,"cells":2193},"Sildenafil",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2212,"NA":2214},{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[2202],{"nctId":2203,"briefTitle":2204,"status":135,"phases":2205,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":2208,"conditions":2209,"interventions":2211},"NCT01295736","Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY",[89],"2013-08","2010-11",84,[2210],"Systemic Scleroderma",[2192],{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":99},[],{"intervention":1132,"totalTrials":95,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2230,"NA":2232},{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[],{"trials":2225,"activeCount":99},[2226],{"nctId":1121,"briefTitle":1122,"status":135,"phases":2227,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":2228,"interventions":2229},[89],[1128,1129,1130],[1132,1133],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[],{"intervention":2235,"totalTrials":95,"cells":2236},"Prophylactic treatment with Wilfactin",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2254,"NA":2256},{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[2245],{"nctId":2246,"briefTitle":2247,"status":1197,"phases":2248,"primaryCompletion":2249,"completion":2249,"start":2250,"enrollment":9,"conditions":2251,"interventions":2253},"NCT02488525","Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support",[89],"2018-09-05","2016-01-20",[2252],"Heart Failure",[2235],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"intervention":2259,"totalTrials":95,"cells":2260},"Tobi Inhalant Product",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2279,"NA":2281},{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[],{"trials":2268,"activeCount":99},[2269],{"nctId":2270,"briefTitle":2271,"status":1197,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":2103,"conditions":2275,"interventions":2277},"NCT03066453","Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis",[89],"2020-01-16","2017-06-13",[2276],"Cystic Fibrosis",[2259,2278],"Nebcin",{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[],{"intervention":2278,"totalTrials":95,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":99},[],{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[],{"trials":2292,"activeCount":99},[2293],{"nctId":2270,"briefTitle":2271,"status":1197,"phases":2294,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":2103,"conditions":2295,"interventions":2296},[89],[2276],[2259,2278],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"intervention":2302,"totalTrials":122,"cells":2303},"A-dopamine",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[2310,2320],{"nctId":2311,"briefTitle":2312,"status":135,"phases":2313,"primaryCompletion":2314,"completion":2314,"start":2315,"enrollment":2316,"conditions":2317,"interventions":2318},"NCT04332276","Dopaminergic restauratIon by intraVEntriculaire Administration",[87,88],"2024-05-06","2020-09-18",12,[29],[2302,2319],"optimized oral treatment",{"nctId":2321,"briefTitle":2322,"status":135,"phases":2323,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":95,"conditions":2326,"interventions":2327},"NCT07214285","Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)",[87,88],"2025-10-30","2025-10-01",[29],[2328],"A-DOPAMINE",{"trials":2330,"activeCount":99},[],{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[],{"intervention":2336,"totalTrials":122,"cells":2337},"Pomalidomide",{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2339,"activeCount":99},[],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[2344,2351],{"nctId":2345,"briefTitle":2346,"status":135,"phases":2347,"primaryCompletion":2348,"completion":1716,"start":1178,"enrollment":2208,"conditions":2349,"interventions":2350},"NCT01053949","IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma",[88],"2014-04",[253],[2336,2336],{"nctId":1503,"briefTitle":1504,"status":135,"phases":2352,"primaryCompletion":1506,"completion":1506,"start":1507,"enrollment":1508,"conditions":2353,"interventions":2354},[88],[253],[1511,377],{"trials":2356,"activeCount":99},[],{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"intervention":2362,"totalTrials":95,"cells":2363},"Formoterol-glycopyrronium co suspension",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2365,"activeCount":99},[],{"trials":2367,"activeCount":99},[],{"trials":2369,"activeCount":99},[2370],{"nctId":2371,"briefTitle":2372,"status":1197,"phases":2373,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":2376,"conditions":2377,"interventions":2378},"NCT04087590","Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient",[88],"2023-03-23","2020-01-14",4,[680],[2362],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"trials":2384,"activeCount":99},[],{"intervention":2386,"totalTrials":95,"cells":2387},"Oseltamivir",{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":99},[],{"trials":2393,"activeCount":99},[2394],{"nctId":2395,"briefTitle":2396,"status":1197,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":2401,"interventions":2403},"NCT03212716","Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.",[88],"2022-05-04","2017-12-23",85,[2402],"Flu",[2386,2404,2405],"Diltiazem","Placebos",{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[],{"trials":2411,"activeCount":99},[],{"intervention":2404,"totalTrials":95,"cells":2413},{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2424,"PHASE4":2426,"NA":2428},{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[2420],{"nctId":2395,"briefTitle":2396,"status":1197,"phases":2421,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":2422,"interventions":2423},[88],[2402],[2386,2404,2405],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[],{"intervention":2405,"totalTrials":95,"cells":2431},{"EARLY_PHASE1":2432,"PHASE1":2434,"PHASE2":2436,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[2438],{"nctId":2395,"briefTitle":2396,"status":1197,"phases":2439,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":2440,"interventions":2441},[88],[2402],[2386,2404,2405],{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[],{"trials":2447,"activeCount":99},[],{"intervention":2449,"totalTrials":95,"cells":2450},"ERIVEDGE",{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"trials":2456,"activeCount":99},[2457],{"nctId":2458,"briefTitle":2459,"status":135,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2465},"NCT02667574","Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)",[88],"2020-07-15","2014-11-18",55,[659],[2449],{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[],{"trials":2471,"activeCount":99},[],{"intervention":2473,"totalTrials":95,"cells":2474},"Imatinib Mesylate and Nilotinib",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[2481],{"nctId":2482,"briefTitle":2483,"status":135,"phases":2484,"primaryCompletion":2485,"completion":2485,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT02891395","Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host",[88],"2017-07-26","2012-12-24",65,[2489],"Graft Versus Host Disease",[2473],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"trials":2496,"activeCount":99},[],{"intervention":2498,"totalTrials":95,"cells":2499},"Adjuvant chemotherapy",{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2504,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[2506],{"nctId":2507,"briefTitle":2508,"status":135,"phases":2509,"primaryCompletion":2510,"completion":2511,"start":2512,"enrollment":1830,"conditions":2513,"interventions":2514},"NCT02662504","Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma",[88],"2018-03-12","2018-03-13","2016-01-16",[460],[2498],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"trials":2520,"activeCount":99},[],{"intervention":2522,"totalTrials":95,"cells":2523},"Revlimid",{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2528,"PHASE3":2539,"PHASE4":2541,"NA":2543},{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[2530],{"nctId":2531,"briefTitle":2532,"status":135,"phases":2533,"primaryCompletion":2534,"completion":1263,"start":1603,"enrollment":2535,"conditions":2536,"interventions":2538},"NCT02302469","Study of Lenalidomide in Relapse\u002FRefractory Waldenstrom Macroglobulinemia",[87,88],"2017-03",17,[2537],"Waldenstrom Macroglobulinemia",[2522],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"intervention":2546,"totalTrials":95,"cells":2547},"Fluconazole",{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[2554],{"nctId":2555,"briefTitle":2556,"status":135,"phases":2557,"primaryCompletion":2558,"completion":2559,"start":2560,"enrollment":596,"conditions":2561,"interventions":2563},"NCT02997059","Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.",[88],"2014-06","2015-06","2008-07",[2562],"Crohn's Disease Aggravated",[2546],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[],{"trials":2569,"activeCount":99},[],{"intervention":2571,"totalTrials":95,"cells":2572},"Pregabalin",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[2579],{"nctId":2580,"briefTitle":2581,"status":1197,"phases":2582,"primaryCompletion":2583,"completion":2583,"start":2584,"enrollment":1556,"conditions":2585,"interventions":2587},"NCT02924675","Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.",[88],"2018-12-12","2015-06-05",[2586],"Earache",[2571],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"intervention":2595,"totalTrials":95,"cells":2596},"IPILIMUMAB",{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"trials":2602,"activeCount":99},[2603],{"nctId":2604,"briefTitle":2605,"status":135,"phases":2606,"primaryCompletion":1506,"completion":1506,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2612},"NCT02662725","Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases",[88],"2012-09",73,[2610,2611],"Melanoma","Brain Metastasis",[2595],{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"intervention":2319,"totalTrials":95,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":99},[],{"trials":2626,"activeCount":99},[2627],{"nctId":2311,"briefTitle":2312,"status":135,"phases":2628,"primaryCompletion":2314,"completion":2314,"start":2315,"enrollment":2316,"conditions":2629,"interventions":2630},[87,88],[29],[2302,2319],{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"intervention":2638,"totalTrials":95,"cells":2639},"daclizumab - sirolimus - tacrolimus",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2658,"PHASE4":2660,"NA":2662},{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[2646],{"nctId":2647,"briefTitle":2648,"status":135,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":16,"conditions":2653,"interventions":2657},"NCT00446264","Islet Allotransplantation With Steroid Free Immunosuppression",[88],"2007-10","2009-02","2003-05",[2654,2655,2656],"Type 1 Diabetes","Hypoglycemia","Metabolic Diseases",[2638],{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":99},[],{"trials":2663,"activeCount":99},[],{"intervention":2665,"totalTrials":95,"cells":2666},"eltrombopag",{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2684,"PHASE4":2686,"NA":2688},{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[2673],{"nctId":2674,"briefTitle":2675,"status":1197,"phases":2676,"primaryCompletion":2677,"completion":2678,"start":2679,"enrollment":27,"conditions":2680,"interventions":2683},"NCT03948529","RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation",[88],"2023-02-24","2023-08-21","2019-09-05",[2681,2682],"Leukemia","Graft Failure",[2665],{"trials":2685,"activeCount":99},[],{"trials":2687,"activeCount":99},[],{"trials":2689,"activeCount":99},[],{"intervention":2691,"totalTrials":95,"cells":2692},"Carfilzomib",{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2697,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[],{"trials":2698,"activeCount":99},[2699],{"nctId":2700,"briefTitle":2701,"status":135,"phases":2702,"primaryCompletion":2703,"completion":2704,"start":2705,"enrollment":2706,"conditions":2707,"interventions":2708},"NCT02302495","Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma",[88],"2016-07-17","2021-07-31","2014-01-08",32,[253],[2691],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"intervention":2716,"totalTrials":95,"cells":2717},"Romiplostim",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[2724],{"nctId":2725,"briefTitle":2726,"status":1197,"phases":2727,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":457,"conditions":2730,"interventions":2733},"NCT02227576","Prevention of Thrombocytopenia in Glioblastoma Patients",[88],"2017-12-14","2014-07-10",[2731,2732],"Thrombocytopenia","Glioblastoma",[2716],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"intervention":2741,"totalTrials":95,"cells":2742},"P28GST",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[2749],{"nctId":2750,"briefTitle":2751,"status":135,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":2754,"enrollment":24,"conditions":2755,"interventions":2757},"NCT02281916","Safety Study of P28GST Treatment in Crohn's Disease Patients",[88],"2018-02","2014-03",[2756],"Crohn's Ileocolitis",[2741],{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"intervention":2765,"totalTrials":95,"cells":2766},"Cytotect®CP",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2768,"activeCount":99},[],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[2773],{"nctId":2774,"briefTitle":2775,"status":1197,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":122,"conditions":2779,"interventions":2781},"NCT05370976","Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.",[88],"2023-08-24","2022-09-13",[2780],"Cytomegalovirus Infections",[2765],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"intervention":2789,"totalTrials":95,"cells":2790},"Donepezil .",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2792,"activeCount":99},[],{"trials":2794,"activeCount":99},[2795],{"nctId":2796,"briefTitle":2797,"status":135,"phases":2798,"primaryCompletion":2799,"completion":2800,"start":1177,"enrollment":481,"conditions":2801,"interventions":2802},"NCT01487395","Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development",[87],"2012-12","2013-12",[231,1202],[2789],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"intervention":2812,"totalTrials":95,"cells":2813},"rSh28GST",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2831,"PHASE3":2833,"PHASE4":2835,"NA":2837},{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[2818],{"nctId":2819,"briefTitle":2820,"status":135,"phases":2821,"primaryCompletion":2822,"completion":2823,"start":2824,"enrollment":2825,"conditions":2826,"interventions":2830},"NCT01512277","Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis",[87],"1999-03","1999-09","1998-09",24,[2827,2828,2829],"Schistosomiasis","Bilharziasis","Urinary Schistosomiasis",[2812],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":99},[],{"intervention":2840,"totalTrials":95,"cells":2841},"Clofarabine",{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2857,"PHASE3":2859,"PHASE4":2861,"NA":2863},{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[2846],{"nctId":2847,"briefTitle":2848,"status":135,"phases":2849,"primaryCompletion":2850,"completion":2851,"start":2852,"enrollment":457,"conditions":2853,"interventions":2856},"NCT01279096","Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia",[87],"2012-06","2013-06","2010-01",[2854,2855],"Acute Lymphoid Leukemia Relapse","Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant",[2840],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[],{"intervention":2866,"totalTrials":95,"cells":2867},"Ganirelix",{"EARLY_PHASE1":2868,"PHASE1":2878,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2869,"activeCount":99},[2870],{"nctId":2871,"briefTitle":2872,"status":135,"phases":2873,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":457,"conditions":2876,"interventions":2877},"NCT05751252","Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.",[86],"2025-02-09","2024-04-17",[316],[2866,2866],{"trials":2879,"activeCount":99},[],{"trials":2881,"activeCount":99},[],{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"intervention":2889,"totalTrials":95,"cells":2890},"Group CRC",{"EARLY_PHASE1":2891,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2892,"activeCount":99},[2893],{"nctId":2894,"briefTitle":2895,"status":135,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2902},"NCT02304978","Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults",[86],"2015-05-26","2009-06-22",26,[2901],"Colorectal Cancer",[2889,2903],"Group control",{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"intervention":2903,"totalTrials":95,"cells":2915},{"EARLY_PHASE1":2916,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2917,"activeCount":99},[2918],{"nctId":2894,"briefTitle":2895,"status":135,"phases":2919,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":2899,"conditions":2920,"interventions":2921},[86],[2901],[2889,2903],{"trials":2923,"activeCount":99},[],{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"intervention":2933,"totalTrials":702,"cells":2934},"Deferiprone",{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2960,"PHASE4":2980,"NA":2982},{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[2941,2951],{"nctId":2942,"briefTitle":2943,"status":135,"phases":2944,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":2103,"conditions":2947,"interventions":2950},"NCT02164253","Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients",[88],"2016-12","2013-09",[2948,2949],"ALS (Amyotrophic Lateral Sclerosis)","Iron Overload",[2933],{"nctId":2952,"briefTitle":2953,"status":135,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":2957,"conditions":2958,"interventions":2959},"NCT02655315","Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease",[88],"2020-09-22","2016-02-09",372,[29],[2933],{"trials":2961,"activeCount":99},[2962,2971],{"nctId":2963,"briefTitle":2964,"status":135,"phases":2965,"primaryCompletion":2966,"completion":2314,"start":2967,"enrollment":2957,"conditions":2968,"interventions":2970},"NCT03293069","Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis",[88,89],"2023-11-11","2019-01-30",[2969],"Amyotrophic Lateral Sclerosis",[2933],{"nctId":2972,"briefTitle":2973,"status":135,"phases":2974,"primaryCompletion":2975,"completion":2976,"start":1178,"enrollment":1265,"conditions":2977,"interventions":2978},"NCT00943748","Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease",[88,89],"2011-08","2011-10",[31],[2979],"deferiprone",{"trials":2981,"activeCount":99},[],{"trials":2983,"activeCount":99},[2984],{"nctId":2985,"briefTitle":2986,"status":135,"phases":2987,"primaryCompletion":2988,"completion":2989,"start":2990,"enrollment":1630,"conditions":2991,"interventions":2993},"NCT02880033","Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes",[91],"2019-10","2020-03","2011-02",[31,2969,2992,2949],"Oxidative Stress",[2979],{"intervention":1721,"totalTrials":1490,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3002,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":99},[],{"trials":2999,"activeCount":99},[],{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[3004],{"nctId":1712,"briefTitle":1713,"status":135,"phases":3005,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":1717,"conditions":3006,"interventions":3007},[89],[1719],[1721,1701],{"trials":3009,"activeCount":99},[],{"trials":3011,"activeCount":99},[3012,3022],{"nctId":3013,"briefTitle":3014,"status":135,"phases":3015,"primaryCompletion":3016,"completion":3016,"start":3017,"enrollment":3018,"conditions":3019,"interventions":3020},"NCT02849236","PECS I Block for Breast Subpectoral Implant Surgery",[91],"2020-07","2016-10-16",56,[1267],[3021],"Ropivacaine",{"nctId":3023,"briefTitle":3024,"status":135,"phases":3025,"primaryCompletion":3026,"completion":3027,"start":2800,"enrollment":3028,"conditions":3029,"interventions":3033},"NCT03185403","The Hemodynamic Effect Between Two Types of Anesthesia in Esophageal Surgery",[91],"2016-07","2017-01",54,[3030,3031,3032],"Epidural Block","Oesophageal Cancer","Oesophagectomy",[1721,3034],"Sufentanil",{"intervention":3036,"totalTrials":122,"cells":3037},"Gliolan",{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":99},[3044],{"nctId":3045,"briefTitle":3046,"status":135,"phases":3047,"primaryCompletion":3048,"completion":3048,"start":3049,"enrollment":16,"conditions":3050,"interventions":3051},"NCT04391062","Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma",[88],"2024-03-25","2021-09-28",[2732],[3036],{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[3058],{"nctId":3059,"briefTitle":3060,"status":135,"phases":3061,"primaryCompletion":3062,"completion":3062,"start":3063,"enrollment":24,"conditions":3064,"interventions":3065},"NCT03048240","INtraoperative photoDYnamic Therapy of GliOblastoma",[91],"2021-04-28","2017-05-05",[2732],[3066],"GLIOLAN",{"intervention":3068,"totalTrials":122,"cells":3069},"Pentoxifylline",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3087,"NA":3089},{"trials":3071,"activeCount":99},[],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[],{"trials":3077,"activeCount":99},[3078],{"nctId":3079,"briefTitle":3080,"status":135,"phases":3081,"primaryCompletion":3082,"completion":1518,"start":3083,"enrollment":3084,"conditions":3085,"interventions":3086},"NCT01214226","Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis",[89],"2010-12","2007-12",278,[141,142],[3068],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[3091],{"nctId":3092,"briefTitle":3093,"status":135,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3098,"interventions":3099},"NCT02796469","Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis",[],"2016-05","2015-05",1974,[141,142],[3068,3100],"Corticosteroid",{"intervention":3102,"totalTrials":122,"cells":3103},"genetic analysis",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":99},[],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[3116,3125],{"nctId":3117,"briefTitle":3118,"status":135,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":1716,"enrollment":457,"conditions":3121,"interventions":3123},"NCT02851134","Search for New Genetic Mutations Major Effect in Crohn's Disease",[],"2018-04",[3122],"Crohn Disease",[3102,3124],"blood and stools samples",{"nctId":3126,"briefTitle":3127,"status":135,"phases":3128,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":3132,"conditions":3133,"interventions":3138},"NCT03055169","TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure",[],"2016-08","2017-08","2012-04",994,[3134,3135,3136,3137],"Genetic Predisposition to Disease","Hyperglycemia","Intensive Care Unit Syndrome","Multiple Organ Failure",[3102,3124],{"intervention":3124,"totalTrials":122,"cells":3140},{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[3153,3157],{"nctId":3117,"briefTitle":3118,"status":135,"phases":3154,"primaryCompletion":3120,"completion":3120,"start":1716,"enrollment":457,"conditions":3155,"interventions":3156},[],[3122],[3102,3124],{"nctId":3126,"briefTitle":3127,"status":135,"phases":3158,"primaryCompletion":3129,"completion":3130,"start":3131,"enrollment":3132,"conditions":3159,"interventions":3160},[],[3134,3135,3136,3137],[3102,3124],{"intervention":3034,"totalTrials":122,"cells":3162},{"EARLY_PHASE1":3163,"PHASE1":3165,"PHASE2":3167,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3164,"activeCount":99},[],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[3169],{"nctId":3170,"briefTitle":3171,"status":135,"phases":3172,"primaryCompletion":3173,"completion":3174,"start":3175,"enrollment":32,"conditions":3176,"interventions":3178},"NCT02962830","Sufentanil Pharmacokinetics After Intra Amniotic Injection",[88],"2024-05-28","2024-05-29","2017-04-19",[3177],"Prenatal Diagnosis",[3034],{"trials":3180,"activeCount":99},[],{"trials":3182,"activeCount":99},[],{"trials":3184,"activeCount":99},[3185],{"nctId":3023,"briefTitle":3024,"status":135,"phases":3186,"primaryCompletion":3026,"completion":3027,"start":2800,"enrollment":3028,"conditions":3187,"interventions":3188},[91],[3030,3031,3032],[1721,3034],{"intervention":3190,"totalTrials":95,"cells":3191},"Bone Marrow +BMP7",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3193,"activeCount":99},[],{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[],{"trials":3203,"activeCount":99},[3204],{"nctId":3205,"briefTitle":3206,"status":1197,"phases":3207,"primaryCompletion":3208,"completion":3208,"start":3209,"enrollment":11,"conditions":3210,"interventions":3212},"NCT02655120","Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult",[91],"2017-05","2005-03",[3211],"Aseptic Necrosis of Femur Head",[3190],{"intervention":3214,"totalTrials":95,"cells":3215},"Infliximab",{"EARLY_PHASE1":3216,"PHASE1":3218,"PHASE2":3220,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3217,"activeCount":99},[],{"trials":3219,"activeCount":99},[],{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[],{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[3228],{"nctId":3229,"briefTitle":3230,"status":1197,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":27,"conditions":3234,"interventions":3235},"NCT03370601","Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases",[91],"2019-01","2017-01-03",[34],[3214,3236,3237,3214],"Mercaptopurine","Azathioprine",{"intervention":3236,"totalTrials":95,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3246,"PHASE4":3248,"NA":3250},{"trials":3241,"activeCount":99},[],{"trials":3243,"activeCount":99},[],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[3252],{"nctId":3229,"briefTitle":3230,"status":1197,"phases":3253,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":27,"conditions":3254,"interventions":3255},[91],[34],[3214,3236,3237,3214],{"intervention":3237,"totalTrials":95,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3264,"PHASE4":3266,"NA":3268},{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":99},[3270],{"nctId":3229,"briefTitle":3230,"status":1197,"phases":3271,"primaryCompletion":3232,"completion":3232,"start":3233,"enrollment":27,"conditions":3272,"interventions":3273},[91],[34],[3214,3236,3237,3214],{"intervention":3275,"totalTrials":95,"cells":3276},"PK-PD genetic polymorphisms",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[],{"trials":3282,"activeCount":99},[],{"trials":3284,"activeCount":99},[],{"trials":3286,"activeCount":99},[],{"trials":3288,"activeCount":99},[3289],{"nctId":3290,"briefTitle":3291,"status":1197,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":1490,"conditions":3295,"interventions":3297},"NCT03172546","Determinants of Oral Anticoagulants' Activity",[],"2019-10-15","2017-07-06",[3296],"Anticoagulant",[3275],{"intervention":3299,"totalTrials":95,"cells":3300},"Immunological diagnosis tests",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":99},[],{"trials":3308,"activeCount":99},[],{"trials":3310,"activeCount":99},[],{"trials":3312,"activeCount":99},[3313],{"nctId":3314,"briefTitle":3315,"status":135,"phases":3316,"primaryCompletion":2989,"completion":2989,"start":3317,"enrollment":3318,"conditions":3319,"interventions":3330},"NCT02972281","Systematic Search for Primary Immunodeficiency in Adults With Infections",[91],"2015-03",120,[3320,3321,3322,3323,3324,3325,3326,3327,3328,3329],"Complement Deficiency","Antibody Deficiency","Chronic Sinus Infection","Meningitis, Bacterial","Pneumonia, Bacterial","Otitis Media","Streptococcal Infection","Neisseria Infections","Haemophilus Influenza","Pneumococcal Infections",[3299],{"intervention":3332,"totalTrials":95,"cells":3333},"Cyproterone Acetate + estradiol",{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3338,"PHASE3":3340,"PHASE4":3342,"NA":3344},{"trials":3335,"activeCount":99},[],{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[],{"trials":3343,"activeCount":99},[],{"trials":3345,"activeCount":99},[3346],{"nctId":3347,"briefTitle":3348,"status":135,"phases":3349,"primaryCompletion":3350,"completion":3350,"start":3351,"enrollment":3352,"conditions":3353,"interventions":3354},"NCT03043924","Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)",[91],"2022-04-15","2017-09-26",52,[316],[3332,3355],"Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral",{"intervention":3355,"totalTrials":95,"cells":3357},{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3364,"PHASE4":3366,"NA":3368},{"trials":3359,"activeCount":99},[],{"trials":3361,"activeCount":99},[],{"trials":3363,"activeCount":99},[],{"trials":3365,"activeCount":99},[],{"trials":3367,"activeCount":99},[],{"trials":3369,"activeCount":99},[3370],{"nctId":3347,"briefTitle":3348,"status":135,"phases":3371,"primaryCompletion":3350,"completion":3350,"start":3351,"enrollment":3352,"conditions":3372,"interventions":3373},[91],[316],[3332,3355],{"intervention":3375,"totalTrials":95,"cells":3376},"blood",{"EARLY_PHASE1":3377,"PHASE1":3379,"PHASE2":3381,"PHASE3":3383,"PHASE4":3385,"NA":3387},{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[],{"trials":3382,"activeCount":99},[],{"trials":3384,"activeCount":99},[],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[3389],{"nctId":3390,"briefTitle":3391,"status":135,"phases":3392,"primaryCompletion":1263,"completion":1263,"start":3393,"enrollment":457,"conditions":3394,"interventions":3396},"NCT03280290","Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft",[91],"2012-03-20",[3395],"Acute Myeloblastic Leukemia",[3375],{"intervention":3398,"totalTrials":95,"cells":3399},"blood analysis",{"EARLY_PHASE1":3400,"PHASE1":3402,"PHASE2":3404,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3401,"activeCount":99},[],{"trials":3403,"activeCount":99},[],{"trials":3405,"activeCount":99},[],{"trials":3407,"activeCount":99},[],{"trials":3409,"activeCount":99},[],{"trials":3411,"activeCount":99},[3412],{"nctId":3413,"briefTitle":3414,"status":135,"phases":3415,"primaryCompletion":3416,"completion":3416,"start":3417,"enrollment":32,"conditions":3418,"interventions":3420},"NCT05550844","Emphysema and FLNA Mutation (E-FLNA)",[],"2023-10-23","2023-02-01",[3419],"Emphysema",[3398],{"intervention":3422,"totalTrials":95,"cells":3423},"biologie sample",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[],{"trials":3429,"activeCount":99},[],{"trials":3431,"activeCount":99},[],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[3436],{"nctId":3437,"briefTitle":3438,"status":135,"phases":3439,"primaryCompletion":3440,"completion":3440,"start":3441,"enrollment":11,"conditions":3442,"interventions":3443},"NCT01713504","Identification of New Markers in the Hypereosinophilic Syndrome",[91],"2015-07","2010-06-29",[945],[3422],{"intervention":3445,"totalTrials":95,"cells":3446},"usual administration of exogenous recombinant FSH",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3453,"PHASE4":3455,"NA":3457},{"trials":3448,"activeCount":99},[],{"trials":3450,"activeCount":99},[],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[3459],{"nctId":3460,"briefTitle":3461,"status":135,"phases":3462,"completion":3463,"start":3464,"enrollment":481,"conditions":3465,"interventions":3467},"NCT00492882","Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome",[],"2007-01","2003-11",[3466],"Anovulation",[3445],{"intervention":3469,"totalTrials":95,"cells":3470},"Oral Glucose",{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3472,"activeCount":99},[],{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[3483],{"nctId":3484,"briefTitle":3485,"status":135,"phases":3486,"primaryCompletion":3487,"completion":3487,"start":3488,"enrollment":1556,"conditions":3489,"interventions":3492},"NCT02525705","Dumping Syndrome After Operation of Esophageal Atresia Type III",[91],"2018-01-15","2011-06-14",[3490,3491],"Oesophageal Atresia","Dumping Syndrome",[3469],{"intervention":3494,"totalTrials":95,"cells":3495},"Anti TNF",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[],{"trials":3507,"activeCount":99},[3508],{"nctId":3509,"briefTitle":3510,"status":1977,"phases":3511,"primaryCompletion":3512,"completion":3512,"start":1544,"enrollment":99,"conditions":3513,"interventions":3515},"NCT02872506","Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection",[91],"2018-08",[3514],"Quality of Life",[3494],{"intervention":3517,"totalTrials":95,"cells":3518},"Monoclonal anti-cd303 antibody",{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3520,"activeCount":99},[],{"trials":3522,"activeCount":99},[],{"trials":3524,"activeCount":99},[],{"trials":3526,"activeCount":99},[],{"trials":3528,"activeCount":99},[],{"trials":3530,"activeCount":99},[3531],{"nctId":3532,"briefTitle":3533,"status":135,"phases":3534,"primaryCompletion":1653,"completion":1653,"start":3535,"enrollment":3536,"conditions":3537,"interventions":3539},"NCT03370627","Effect of Anti-CD303 Antibodies in Autoimmune Diseases",[91],"2017-12-20",138,[3538],"Immune Disease",[3517],{"intervention":3541,"totalTrials":95,"cells":3542},"Diazepam",{"EARLY_PHASE1":3543,"PHASE1":3545,"PHASE2":3547,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":99},[],{"trials":3552,"activeCount":99},[],{"trials":3554,"activeCount":99},[3555],{"nctId":3556,"briefTitle":3557,"status":135,"phases":3558,"primaryCompletion":3026,"completion":3026,"start":1375,"enrollment":2899,"conditions":3559,"interventions":3561},"NCT02242955","Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse",[91],[3560],"Alcoholism",[3541],{"intervention":3563,"totalTrials":95,"cells":3564},"Tofacitinib",{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3569,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3566,"activeCount":99},[],{"trials":3568,"activeCount":99},[],{"trials":3570,"activeCount":99},[],{"trials":3572,"activeCount":99},[],{"trials":3574,"activeCount":99},[],{"trials":3576,"activeCount":99},[3577],{"nctId":3578,"briefTitle":3579,"status":135,"phases":3580,"primaryCompletion":3581,"completion":3581,"start":3582,"enrollment":24,"conditions":3583,"interventions":3585},"NCT04175886","Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project",[],"2023-05-08","2020-02-25",[3584],"Rheumatoid Arthritis",[3563],{"intervention":3587,"totalTrials":95,"cells":3588},"Biological",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3590,"activeCount":99},[],{"trials":3592,"activeCount":99},[],{"trials":3594,"activeCount":99},[],{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"trials":3600,"activeCount":99},[3601],{"nctId":3602,"briefTitle":3603,"status":135,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3610},"NCT02839317","COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)",[],"2022-12-22","2016-05-09",214,[3609],"Crohn's Disease",[3587],{"intervention":3100,"totalTrials":95,"cells":3612},{"EARLY_PHASE1":3613,"PHASE1":3615,"PHASE2":3617,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"trials":3618,"activeCount":99},[],{"trials":3620,"activeCount":99},[],{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[3625],{"nctId":3092,"briefTitle":3093,"status":135,"phases":3626,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3627,"interventions":3628},[],[141,142],[3068,3100],{"intervention":3630,"totalTrials":95,"cells":3631},"Analysis of genetic polymorphisms",{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3636,"PHASE3":3638,"PHASE4":3640,"NA":3642},{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[],{"trials":3637,"activeCount":99},[],{"trials":3639,"activeCount":99},[],{"trials":3641,"activeCount":99},[],{"trials":3643,"activeCount":99},[3644],{"nctId":3645,"briefTitle":3646,"status":135,"phases":3647,"primaryCompletion":3648,"completion":3648,"start":2851,"enrollment":3649,"conditions":3650,"interventions":3653},"NCT02841501","Genetic Susceptibility Factors for Candidemia.",[],"2020-06-25",453,[3651,3652,3134],"Invasive Candidiasis","Candidemia",[3630],{"intervention":3655,"totalTrials":95,"cells":3656},"Detection of anti-Anisakis and anti-fish antibodies",{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3663,"PHASE4":3665,"NA":3667},{"trials":3658,"activeCount":99},[],{"trials":3660,"activeCount":99},[],{"trials":3662,"activeCount":99},[],{"trials":3664,"activeCount":99},[],{"trials":3666,"activeCount":99},[],{"trials":3668,"activeCount":99},[3669],{"nctId":3670,"briefTitle":3671,"status":135,"phases":3672,"primaryCompletion":3027,"completion":3027,"start":3673,"enrollment":3674,"conditions":3675,"interventions":3679},"NCT02666092","Anisakis Blastocystis Cryptosporidium Fish Serology",[],"2015-02",105,[3676,3677,3678],"Allergy to Fish","Allergy","Anisakis",[3655],{"intervention":3681,"totalTrials":95,"cells":3682},"Blood and\u002For skin biopsy",{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3684,"activeCount":99},[],{"trials":3686,"activeCount":99},[],{"trials":3688,"activeCount":99},[],{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[],{"trials":3694,"activeCount":99},[3695],{"nctId":3696,"briefTitle":3697,"status":1197,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":3700,"enrollment":3701,"conditions":3702,"interventions":3707},"NCT04658251","Study of New Mutations in Cone Disorders",[],"2024-04-14","2021-03-03",7,[3703,3704,3705,3706],"Retinal Dystrophy, Cone-Rod","Cone Dystrophy","Cone Rod Dystrophy","Macular Degeneration",[3681],{"intervention":3709,"totalTrials":95,"cells":3710},"GED",{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3717,"PHASE4":3719,"NA":3721},{"trials":3712,"activeCount":99},[],{"trials":3714,"activeCount":99},[],{"trials":3716,"activeCount":99},[],{"trials":3718,"activeCount":99},[],{"trials":3720,"activeCount":99},[],{"trials":3722,"activeCount":99},[3723],{"nctId":3724,"briefTitle":3725,"status":135,"phases":3726,"primaryCompletion":1544,"completion":1544,"start":3727,"enrollment":1483,"conditions":3728,"interventions":3730},"NCT02902016","Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies",[91],"2015-07-16",[3729],"Lactose Intolerance",[3709],{"intervention":3732,"totalTrials":95,"cells":3733},"Remifentanil",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3735,"activeCount":99},[],{"trials":3737,"activeCount":99},[],{"trials":3739,"activeCount":99},[],{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":99},[],{"trials":3745,"activeCount":99},[3746],{"nctId":3747,"briefTitle":3748,"status":135,"phases":3749,"primaryCompletion":3750,"completion":3751,"start":3752,"enrollment":3352,"conditions":3753,"interventions":3756},"NCT03556696","Automatic Remifentanil Administration Guided by ANI During Propofol Anesthesia",[91],"2022-06-14","2022-11-22","2018-06-27",[3754,3755],"Nociceptive Pain","Surgical Procedure, Unspecified",[3732,3757],"Propofol",{"intervention":3757,"totalTrials":95,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3761,"activeCount":99},[],{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[3772],{"nctId":3747,"briefTitle":3748,"status":135,"phases":3773,"primaryCompletion":3750,"completion":3751,"start":3752,"enrollment":3352,"conditions":3774,"interventions":3775},[91],[3754,3755],[3732,3757],{"intervention":3777,"totalTrials":95,"cells":3778},"Plasma dosage",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3780,"activeCount":99},[],{"trials":3782,"activeCount":99},[],{"trials":3784,"activeCount":99},[],{"trials":3786,"activeCount":99},[],{"trials":3788,"activeCount":99},[],{"trials":3790,"activeCount":99},[3791],{"nctId":3792,"briefTitle":3793,"status":135,"phases":3794,"primaryCompletion":3795,"completion":3795,"start":3796,"enrollment":3797,"conditions":3798,"interventions":3799},"NCT03483792","Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin",[],"2022-06-02","2018-04-20",58,[316],[3777,3800],"placental biopsy",{"intervention":3800,"totalTrials":95,"cells":3802},{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3807,"PHASE3":3809,"PHASE4":3811,"NA":3813},{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[],{"trials":3808,"activeCount":99},[],{"trials":3810,"activeCount":99},[],{"trials":3812,"activeCount":99},[],{"trials":3814,"activeCount":99},[3815],{"nctId":3792,"briefTitle":3793,"status":135,"phases":3816,"primaryCompletion":3795,"completion":3795,"start":3796,"enrollment":3797,"conditions":3817,"interventions":3818},[],[316],[3777,3800],{"intervention":3820,"totalTrials":95,"cells":3821},"Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration",{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3828,"PHASE4":3830,"NA":3832},{"trials":3823,"activeCount":99},[],{"trials":3825,"activeCount":99},[],{"trials":3827,"activeCount":99},[],{"trials":3829,"activeCount":99},[],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[3834],{"nctId":3835,"briefTitle":3836,"status":135,"phases":3837,"primaryCompletion":3838,"completion":3838,"start":3839,"enrollment":3840,"conditions":3841,"interventions":3843},"NCT04760704","Covid-19 Vaccine Response in Elderly Subjects",[],"2023-03-28","2021-02-18",264,[3842],"Covid19 Vaccine",[3820],{"intervention":3845,"totalTrials":95,"cells":3846},"antibiotic treatment",{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3848,"activeCount":99},[],{"trials":3850,"activeCount":99},[],{"trials":3852,"activeCount":99},[],{"trials":3854,"activeCount":99},[],{"trials":3856,"activeCount":99},[],{"trials":3858,"activeCount":99},[3859],{"nctId":3860,"briefTitle":3861,"status":135,"phases":3862,"primaryCompletion":3863,"completion":3864,"start":3865,"enrollment":3797,"conditions":3866,"interventions":3869},"NCT00122057","Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis",[91],"2007-05","2007-06","2005-06",[3867,3868],"Respiratory Tract Diseases","Nosocomial Infections",[3845],{"intervention":3871,"totalTrials":95,"cells":3872},"paracetamol",{"EARLY_PHASE1":3873,"PHASE1":3875,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3874,"activeCount":99},[],{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[],{"trials":3884,"activeCount":99},[3885],{"nctId":3886,"briefTitle":3887,"status":135,"phases":3888,"primaryCompletion":3120,"completion":3889,"start":3890,"enrollment":1630,"conditions":3891,"interventions":3894},"NCT03297073","Paracetamol Metabolism Research in Postoperative Hepatic Surgery",[91],"2019-11","2016-11-20",[3892,3893],"Paracetamol Causing Adverse Effects in Therapeutic Use","Hepatic Disease",[3871]]